Remove Clinical Trials Remove Medicine Remove Programs Remove Sleep
article thumbnail

Incannex (ASX: IHL) partners with Procaps to develop cannabis medicine for clinical trial on sleep apnea

Cannabis Law Report

to develop and manufacture soft gel capsules of Incannex’s cannabis medicine IHL-42X. The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. According to an article from the Lancet, sleep apnea affects 936 million adults globally.

article thumbnail

Vice Article: Australians Can Get a Medicinal Cannabis Prescription for Pretty Much Anything

Cannabis Law Report

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. 11 May 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

More than half of prescriptions for medicinal cannabis in Australia given in Queensland, study says

Cannabis Law Report

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The researchers’ analysis found anxiety was the reason given for 16% of medicinal cannabis prescriptions. of prescriptions were for sleep disorders. The Guardian writes.

article thumbnail

Press Release: Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

Cannabis Law Report

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression. Optimi Health Corp.

article thumbnail

Press Release: Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

Cannabis Law Report

“Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.

Therapy 52
article thumbnail

Unlocking the Potential of CBD: Exploring The Benefits of CBD in Medical Marijuana

MMJ Recs

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Sleep disturbances are prevalent among individuals of all ages and can have a profound impact on overall health and well-being.

CBD 52
article thumbnail

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Cannabis Law Report

Psychedelics, medicine and ethics has always been a tricky thing and we’re suprised (or maybe not) that those who have held themselves up to be the paragons of perfection in the field over the past few years, have in fact been either arrogant, dumb or lazy when it comes to managing ethics at their organisations.